Consolidated Statements of Operations (USD $) In Thousands, except Share data, unless otherwise specified	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010
Revenues:
Product sales, net	$ 6,729	$ 5,163
Research and development income	921	666
Licensing and royalty income	100	248
Other revenue	56	17
Total revenues	7,806	6,094
Costs and Expenses:
Cost of sales	5,546	4,989
Selling, general and administrative expenses	3,078	3,226
Product development and research expenses	2,151	1,510
Total costs and expenses	10,775	9,725
Operating loss	(2,969)	(3,631)
Interest expense	(281)	(10)
Interest and other income, net	17	1
Loss before benefit from income taxes	(3,233)	(3,640)
Benefit from income taxes	226	217
Net loss	(3,007)	(3,423)
Preferred stock dividends		(1,284)
Net loss attributable to common stockholders	$ (3,007)	$ (4,707)
Basic and diluted loss per common share (in Dollars per share)	$ (0.08)	$ (0.20)
Weighted average shares of common stock outstanding
Basic and diluted (in Shares)	39,448,706	23,822,167